Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$7.89 +1.1%	$6.69	$5.01 ▼ $18.71	$47.18M	0.3	124,596 shs	6,935 shs
DTIL Precision BioSciences	$4.99 +0.3%	$4.95	$3.61 ▼ $13.32	$55.33M	1.55	183,524 shs	6,963 shs
KPTI Karyopharm Therapeutics	$4.51 +0.7%	$5.10	$3.51 ▼ $17.40	$38.99M	0.33	104,332 shs	14,890 shs
TLPH Talphera	$0.50 +0.9%	$0.52	$0.45 ▼ $1.19	$10.19M	-0.15	57,026 shs	15,660 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	+4.14%	+13.04%	+5.12%	+13.21%	-48.98%
DTIL Precision BioSciences	+1.64%	+6.88%	-2.74%	-9.47%	-60.71%
KPTI Karyopharm Therapeutics	-1.54%	-4.68%	-26.19%	-46.35%	-69.94%
TLPH Talphera	-1.85%	-2.76%	+2.67%	-14.79%	-52.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATRA Atara Biotherapeutics	4.3423 of 5 stars	3.3	3.0	4.7	3.4	2.5	0.6
DTIL Precision BioSciences	3.7496 of 5 stars	3.5	2.0	4.6	1.0	1.7	0.6
KPTI Karyopharm Therapeutics	3.9945 of 5 stars	3.5	0.0	4.6	3.6	2.5	0.6
TLPH Talphera	2.153 of 5 stars	3.8	2.0	0.0	2.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.57	Moderate Buy	$17.75	125.08% Upside
DTIL Precision BioSciences	3.00	Buy	$47.00	842.83% Upside
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	857.23% Upside
TLPH Talphera	3.50	Strong Buy	$5.00	906.04% Upside

Current Analyst Ratings Breakdown

Latest TLPH, KPTI, DTIL, and ATRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00
4/1/2025	TLPH Talphera	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/28/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
3/19/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
3/11/2025	ATRA Atara Biotherapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
3/3/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$75.00 ➝ $54.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$199.73M	0.24	N/A	N/A	($24.34) per share	-0.32
DTIL Precision BioSciences	$51.14M	1.08	N/A	N/A	$4.53 per share	1.10
KPTI Karyopharm Therapeutics	$142.13M	0.27	N/A	N/A	($1.47) per share	-3.07
TLPH Talphera	$27K	377.41	N/A	N/A	$0.83 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	-$276.13M	-$3.72	N/A	N/A	N/A	-132.58%	N/A	-90.16%	8/11/2025 (Estimated)
DTIL Precision BioSciences	-$61.32M	-$2.01	83.18	N/A	N/A	11.48%	-23.69%	-6.98%	7/30/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$143.10M	-$13.26	N/A	N/A	N/A	-52.62%	N/A	-39.58%	8/5/2025 (Estimated)
TLPH Talphera	-$18.40M	-$0.45	N/A	N/A	N/A	N/A	-118.46%	-65.82%	8/12/2025 (Estimated)

Latest TLPH, KPTI, DTIL, and ATRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	$3.50	+$6.57	$3.50	$4.30 million	$98.10 million
5/15/2025	Q1 2025	DTIL Precision BioSciences	-$0.43	-$2.21	-$1.78	-$2.21	$5.00 million	$0.03 million
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
3/31/2025	Q4 2024	TLPH Talphera	-$0.21	-$0.07	+$0.14	-$0.07	N/A	N/A
3/26/2025	Q4 2024	DTIL Precision BioSciences	-$2.09	-$3.20	-$1.11	-$2.22	$4.28 million	$3.47 million
3/7/2025	Q4 2024	ATRA Atara Biotherapeutics	-$3.82	-$1.19	+$2.63	-$1.19	$20.58 million	$32.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	0.59	0.50
DTIL Precision BioSciences	0.34	9.22	9.22
KPTI Karyopharm Therapeutics	N/A	1.70	2.93
TLPH Talphera	N/A	4.42	4.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
DTIL Precision BioSciences	37.99%
KPTI Karyopharm Therapeutics	66.44%
TLPH Talphera	37.67%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	3.70%
DTIL Precision BioSciences	4.50%
KPTI Karyopharm Therapeutics	2.75%
TLPH Talphera	3.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	5.96 million	5.55 million	Optionable
DTIL Precision BioSciences	200	11.09 million	7.36 million	No Data
KPTI Karyopharm Therapeutics	380	8.64 million	122.72 million	Optionable
TLPH Talphera	19	20.50 million	16.48 million	Optionable

TLPH, KPTI, DTIL, and ATRA Headlines

Recent News About These Companies

Talphera (NASDAQ:TLPH) Stock Price Up 0.4% - Here's Why

May 24, 2025 | americanbankingnews.com

Talphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 17, 2025 | finanznachrichten.de

Earnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025

May 16, 2025 | uk.investing.com

Talphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call Transcript

May 16, 2025 | msn.com

Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing

May 15, 2025 | msn.com

Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | prnewswire.com

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

May 7, 2025 | prnewswire.com

All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy

May 7, 2025 | msn.com

Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock?

April 5, 2025 | msn.com

Talphera reports Q4 EPS (7c) vs. (25c) last year

April 1, 2025 | markets.businessinsider.com

Talphera, Inc. (NASDAQ:TLPH) Q4 2024 Earnings Call Transcript

April 1, 2025 | msn.com

Talphera announces agreement with FDA to reduce NEPHRO CRRT study size

April 1, 2025 | markets.businessinsider.com

Talphera Reports 2024 Financial Results and Study Update

March 31, 2025 | tipranks.com

Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad

March 31, 2025 | msn.com

Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript

March 31, 2025 | seekingalpha.com

Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 31, 2025 | prnewswire.com

Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million

March 31, 2025 | prnewswire.com

7TLPH : Earnings Outlook For Talphera

March 28, 2025 | benzinga.com

Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025

March 26, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH, KPTI, DTIL, and ATRA Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$7.89 +0.09 (+1.10%)

As of 11:39 AM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Precision BioSciences NASDAQ:DTIL

$4.99 +0.02 (+0.30%)

As of 11:41 AM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Karyopharm Therapeutics NASDAQ:KPTI

$4.51 +0.03 (+0.74%)

As of 11:43 AM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Talphera NASDAQ:TLPH

$0.50 +0.00 (+0.93%)

As of 11:41 AM Eastern

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time